Sunday, July 5, 2015

QR Pharma of Berwyn gets cash from Michael J. Fox Foundation

Actor Michael J. Fox has Parkinson's disease and his foundation's efforts to fight the disease will translate into $468,000 for QR Pharma, a Berwyn start up.

QR Pharma of Berwyn gets cash from Michael J. Fox Foundation

0 comments

Actor Michael J. Fox has Parkinson's disease and his foundation's efforts to fight the disease will translate into $468,000 for QR Pharma, a Berwyn start up, according to the company.

QR Pharma, Inc. is a clinical stage specialty pharmaceutical company trying to develop drugs to treat Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders.

The Michael J. Fox Foundation for Parkinson’s Research gave QR Pharma the money to conduct research for the development of a drug called Posiphen to treat Parkinson's.

QR says it will collaborate with Dr. Robert Nussbaum, a professor in the genetics department at the University of California, San Francisco, and Jack T. Rogers, an associate professor of psychiatry (neuroscience) in the genetics and aging research unit at Massachusetts General Hospital.

“We are pleased that The Michael J. Fox Foundation for Parkinson’s Research sees the potential of Posiphen in the treatment of Parkinson’s disease,” Maria Maccecchini, QR Pharma's chief executive officer, said in a statement. “We look forward to working with the excellent research teams led by Dr. Nussbaum and Dr. Rogers.”

 

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Also on Philly.com:
letter icon Newsletter